EXOZ
HEALTHCAREInvizyne Technologies Inc
$10.54+0.65 (+6.59%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving EXOZ Today?
No stock-specific AI insight has been generated for EXOZ yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.08$18.40
$10.54
Fundamentals
Market Cap$89M
P/E Ratio—
EPS$-1.09
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin—
Debt / Equity—
Trading
Volume2K
Avg Volume (10D)—
Shares Outstanding8.5M
EXOZ News
20 articles- eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) ProgramYahoo Finance·May 7, 2026
- eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything PodcastYahoo Finance·Apr 10, 2026
- MDB Capital Holdings LLC (MDBH) Q4 2025 Earnings Call Highlights: Strategic Innovations and ...Yahoo Finance·Apr 7, 2026
- EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesYahoo Finance·Apr 1, 2026
- eXoZymes Q4 Earnings Call HighlightsMarketbeat·Mar 31, 2026
- eXoZymes Provides Fourth Quarter and Full Year 2025 UpdateYahoo Finance·Mar 31, 2026
- MDB Capital Holdings Provides 2025 Full Year Update and Shareholder LetterYahoo Finance·Mar 31, 2026
- eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026Yahoo Finance·Mar 25, 2026
- Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and ScalabilityYahoo Finance·Mar 18, 2026
- eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA SymposiumYahoo Finance·Mar 12, 2026
- With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value CreationYahoo Finance·Feb 10, 2026
- eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot RunYahoo Finance·Jan 30, 2026
- eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock ConversionYahoo Finance·Dec 11, 2025
- EXoZymes Inc (EXOZ) Q3 2025 Earnings Call Highlights: Unlocking Market Opportunities Amid ...Yahoo Finance·Nov 14, 2025
- eXoZymes Provides Third Quarter 2025 Update at 5PM EST TodayYahoo Finance·Nov 13, 2025
- eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of StaffYahoo Finance·Nov 13, 2025
- eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM ESTYahoo Finance·Nov 10, 2025
- CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment ConferenceYahoo Finance·Oct 30, 2025
- CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor ConferenceYahoo Finance·Oct 29, 2025
- CEO of eXoZymes to Present at ThinkEquity's Annual Investor ConferenceYahoo Finance·Oct 23, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$9.89
Day High$0.00
Day Low$0.00
52 Week High$18.40
52 Week Low$7.08
52-Week Range
$7.08$18.40
$10.54
Fundamentals
Market Cap$89M
P/E Ratio—
EPS$-1.09
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin—
Debt / Equity—
Trading
Volume2K
Avg Volume (10D)—
Shares Outstanding8.5M
About Invizyne Technologies Inc
eXoZymes, Inc. is a synthetic biochemical company in the United States. The company is headquartered in Monrovia, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—